Literature DB >> 26573674

[Priapism: Current diagnostics and therapy].

B Schwindl1, T Bschleipfer2, T Klotz3.   

Abstract

Priapism is characterized by involuntary persistent penile erection after or independent of sexual stimulation. The diagnostic clarification, including patient history, physical findings, duplex ultrasonography and analysis of blood gases is decisive for the underlying pathophysiology and the appropriate therapeutic procedure. Non-hypoxic and non-acidotic blood gas parameters enable a conservative approach, hypoxic, hypercarbic and acidotic parameters may lead to fibrosis of the corpora cavernosa and, in turn, to a loss of penile function. Low-flow or ischemic (veno-occlusive) priapism is an emergency situation and can lead to irreversible erectile dysfunction within 4 h. Treatment consists of blood aspiration and possibly intracavernosal injection of sympathomimetic drugs. A distal shunt is necessary in the case of treatment failure (in rare cases a proximal shunt). Management of recurrent priapism (stuttering) includes self-injection of sympathomimetic drugs and preventive long-term administration of erection inhibitory and erection promoting substances. This concept still needs to be validated. High-flow or non-ischemic priapism does not necessitate immediate treatment measures and should be kept under observation. In cases of a detectable fistula selective artery embolization is often a successful option.

Entities:  

Keywords:  High-flow priapism; Ischemic priapism; Low-flow priapism; Recurrent priapism; Stuttering priapism

Mesh:

Substances:

Year:  2015        PMID: 26573674     DOI: 10.1007/s00120-015-3987-9

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  23 in total

1.  Management of sickle cell priapism with etilefrine.

Authors:  A D Gbadoé; Y Atakouma; K Kusiaku; J K Assimadi
Journal:  Arch Dis Child       Date:  2001-07       Impact factor: 3.791

2.  Sildenafil relieves priapism in patients with sickle cell disease.

Authors:  Eldad S Bialecki; Kenneth R Bridges
Journal:  Am J Med       Date:  2002-08-15       Impact factor: 4.965

3.  VENOUS BYPASS TO CONTROL PRIAPISM.

Authors:  J T GRAYHACK; W MCCULLOUGH; V J O'CONOR; O TRIPPEL
Journal:  Invest Urol       Date:  1964-03

4.  Cure of idiopathic priapism: new procedure for creating fistula between glans penis and corpora cavernosa.

Authors:  C C Winter
Journal:  Urology       Date:  1976-10       Impact factor: 2.649

5.  Treatment of intermittent idiopathic priapism with oral terbutaline.

Authors:  I Ahmed; N A Shaikh
Journal:  Br J Urol       Date:  1997-08

6.  Daily phosphodiesterase type 5 inhibitor therapy as rescue for recurrent ischemic priapism after failed androgen ablation.

Authors:  Phillip M Pierorazio; Trinity J Bivalacqua; Arthur L Burnett
Journal:  J Androl       Date:  2010-12-02

Review 7.  European Association of Urology guidelines on priapism.

Authors:  Andrea Salonia; Ian Eardley; François Giuliano; Dimitrios Hatzichristou; Ignacio Moncada; Yoram Vardi; Eric Wespes; Konstantinos Hatzimouratidis
Journal:  Eur Urol       Date:  2013-11-16       Impact factor: 20.096

8.  Successful management of stuttering priapism using home self-injections of the alpha-agonist metaraminol.

Authors:  Michael McDonald; Richard A Santucci
Journal:  Int Braz J Urol       Date:  2004 Mar-Apr       Impact factor: 1.541

9.  Gonadotropin-releasing hormone analogues in the treatment of sickle cell anemia-associated priapism.

Authors:  L A Levine; S P Guss
Journal:  J Urol       Date:  1993-08       Impact factor: 7.450

10.  Sickle cell disease status and outcomes of African-American men presenting with priapism.

Authors:  Nelson Bennett; John Mulhall
Journal:  J Sex Med       Date:  2008-02-25       Impact factor: 3.802

View more
  1 in total

1.  [Prophylaxis of recurring low-flow priapism : Experimental botulinum neurotoxin injection into the ischiocavernosus muscle].

Authors:  G Reichel; A Stenner
Journal:  Urologe A       Date:  2018-01       Impact factor: 0.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.